Newsbenzinga
Quoin Pharmaceuticals Establishes Japanese Subsidiary To Commercialize QRX003 For The Treatment Of Netherton Syndrome Upon Approval By Authorities
· Published
Article summary
Please check the source for details.
An excerpt from the original article.
Comments —
Loading comments…